Compounds / Tissue Repair / Cartalax

Cartalax

Cartalax (AC-4 Bioregulatory Tripeptide)
Tissue RepairEmerging ResearchFDA: Not approved

Overview

Russian clinical studies: osteoarthritis and osteochondrosis benefits at 100mcg oral. Preventive use in elderly for degenerative joint disease. Post-fracture recovery support. Synergistic with glucosamine/chondroitin and BPC-157.

Mechanism of Action

Khavinson bioregulator tripeptide with cartilage and connective tissue specificity. Stimulates fibroblast proliferation and metabolic activity. Supports collagen synthesis in joint tissue. Anti-aging effects on cartilage matrix via direct DNA interaction in target cells.

Molecular Profile

Molecular weight
~300 Da

Key Research Findings

Fibroblast activation; cartilage matrix support; Khavinson bioregulator; Russian osteoarthritis studies; anti-sclerotic.

Related Tissue Repair Compounds

BPC-157TB-500AHK-CuKPVMGFPEG-MGF
Clinical Guidance

Research data is not a treatment plan. If you are considering Cartalax, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Cartalax? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals